Avalyn Pharma Presents AP01 Lung Distribution Data at ERS Congress 2026
Avalyn Pharma shared modeling data suggesting its inhaled drug AP01 reaches fibrotic lungs effectively, even in severe disease.
Computer modeling of Avalyn Pharma's experimental inhaled drug AP01 predicts it can distribute robustly throughout both healthy and fibrotic lungs, including in patients with severe disease — a key hurdle for inhaled therapies targeting lung fibrosis. The Boston-based clinical-stage biopharmaceutical company presented this in silico data at the European Respiratory Society (ERS) Congress 2026, a major international pulmonology conference. Avalyn (Nasdaq: AVLN) is developing AP01 as part of its focus on rare, serious respiratory conditions. Separately, the company announced its management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on September 8, 2026, a common venue for investor-facing updates from clinical-stage biotechs.
Why it matters
Effective drug distribution in fibrotic — scarred and stiffened — lung tissue is a significant scientific challenge, and positive modeling data can support the case for advancing AP01 into or through clinical trials. Investors and patients with rare fibrotic lung diseases may watch these developments closely.
What's next
Avalyn management is scheduled to present at the Morgan Stanley Global Healthcare Conference on September 8, 2026, where further updates on AP01's development may be shared.
Key facts
- AP01 is Avalyn Pharma's inhaled experimental drug targeting rare fibrotic lung diseases
- In silico (computer-based) modeling predicts AP01 distributes robustly in both healthy and fibrotic lungs, including severe disease
- Data was presented at the European Respiratory Society (ERS) Congress 2026
- Avalyn Pharma trades on Nasdaq under the ticker AVLN and is headquartered in Boston
- Avalyn management is participating in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on September 8, 2026
Bias & framing notes
All three sources are press release reprintings via GlobeNewswire, meaning there is no independent journalism or third-party verification — the content reflects Avalyn's own framing. The ERS Congress data headline is truncated, so key details about what exactly was presented remain unavailable. No independent scientific or financial commentary is included.
NewsClear — neutral news & congressional tracking · Bill of the Week